The prevalence of STING positivity was intermediate for urothelial neoplasms (51.3–79.6%), adenocarcinoma of the esophagus (57.4%), and several important sarcoma categories such as liposarcoma (50.9%) and osteosarcoma (48.3%). This evidence concerns the gene STING1 and sarcoma.